Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Net Income (2016 - 2025)

Guided Therapeutics' Net Income history spans 15 years, with the latest figure at -$742000.0 for Q3 2025.

  • For Q3 2025, Net Income fell 13.46% year-over-year to -$742000.0; the TTM value through Sep 2025 reached -$2.6 million, down 22.27%, while the annual FY2024 figure was -$2.4 million, 30.73% up from the prior year.
  • Net Income for Q3 2025 was -$742000.0 at Guided Therapeutics, up from -$809000.0 in the prior quarter.
  • Across five years, Net Income topped out at -$75000.0 in Q3 2021 and bottomed at -$1.8 million in Q4 2022.
  • The 5-year median for Net Income is -$677000.0 (2023), against an average of -$752368.4.
  • The largest annual shift saw Net Income soared 84.68% in 2021 before it crashed 1369.33% in 2022.
  • A 5-year view of Net Income shows it stood at -$444000.0 in 2021, then crashed by 306.98% to -$1.8 million in 2022, then soared by 78.64% to -$386000.0 in 2023, then plummeted by 68.91% to -$652000.0 in 2024, then decreased by 13.8% to -$742000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Net Income are -$742000.0 (Q3 2025), -$809000.0 (Q2 2025), and -$427000.0 (Q1 2025).